Skip to main content
. Author manuscript; available in PMC: 2024 Jul 17.
Published in final edited form as: Clin Cancer Res. 2024 Jan 17;30(2):274–282. doi: 10.1158/1078-0432.CCR-23-1200

Figure 3: Grade ≥3 (per NCI’s CTCAE v3) non-hematologic adverse events in all 25 patients through day 100.

Figure 3:

Adverse events were collected and graded according to NCI’s Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3), from first exposure of radiolabeled BC8 through day +100 after HCT, or prior to day +100 if patients were discharged before.